News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Karl Thiel
Biotech Bay
BioPharm Executive: Money Talk
Venture capital is hopping, attracted to some of the past several years’ successes.
October 14, 2017
·
1 min read
·
Karl Thiel
Business
BioPharm Executive: Golden Handshakes
Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.
October 14, 2017
·
1 min read
·
Karl Thiel
Business
BioPharm Executive: Career Track
Kare Schultz will become Teva’s fourth CEO in a decade, and its second outsider.
October 14, 2017
·
1 min read
·
Karl Thiel
Drug Development
BioPharm Executive: From the Bench to the Clinic
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
October 14, 2017
·
1 min read
·
Karl Thiel
